KR20020031342A - 피복된 라니티딘, 비스마스 서브시트레이트 및수크랄페이트를 함유하는 경구용 위장질환 치료용 약제조성물 - Google Patents
피복된 라니티딘, 비스마스 서브시트레이트 및수크랄페이트를 함유하는 경구용 위장질환 치료용 약제조성물 Download PDFInfo
- Publication number
- KR20020031342A KR20020031342A KR1020017016389A KR20017016389A KR20020031342A KR 20020031342 A KR20020031342 A KR 20020031342A KR 1020017016389 A KR1020017016389 A KR 1020017016389A KR 20017016389 A KR20017016389 A KR 20017016389A KR 20020031342 A KR20020031342 A KR 20020031342A
- Authority
- KR
- South Korea
- Prior art keywords
- ranitidine
- coated
- sucralate
- subcitrate
- film
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/29—Antimony or bismuth compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
Abstract
Description
시험군 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
실시예4 | 34.5 | 38.8 | 35.1 | 37.3 | 36.4 | 35.3 | 37.9 | 34.8 | 39.2 | 38.5 |
비교예 | 6.2 | 6.8 | 7.4 | 7.8 | 6.1 | 6.6 | 7.2 | 6.3 | 7.5 | 6.7 |
시험군 | 피험자수(명) | AUC(ng/hr/ml) | Cmax(ng/ml) | Tmax(hr) |
실시예1 | 6 | 2285 ±115.2* | 485.3 ±30.6* | 2.86 ±0.29 |
실시예4 | 6 | 2354 ±103.5* | 493.4 ±31.2* | 2.69 ±0.35 |
비교예 | 6 | 1623 ±98.6 | 293.7 ±34.6 | 3.23 ±0.41 |
시험군 | 피험자수(명) | 완치된 환자수(명) | 치료율(%) |
실시예1 | 5 | 4 | 80 |
실시예4 | 5 | 5 | 100 |
비교예 | 5 | 3 | 60 |
Claims (8)
- 피막 파열시간이 20 내지 90분인 피막 형성 조성물로 피복된 라니티딘, 비스마스 서브시트레이트 및 수크랄페이트가 활성성분으로 함유되어 있는 것을 특징으로 하는 경구용 위장질환 치료용 약제 조성물.
- 제 1항에 있어서, 상기 라니티딘의 피막 파열시간이 30 내지 70분인 것을 특징으로 하는 약제 조성물.
- 제 1항에 있어서, 상기 피막 형성 조성물은 전체 라니티딘 조성물 중량에 대하여 0.1 내지 10.0 중량%로 포함되는 것을 특징으로 하는 약제 조성물.
- 제 3항에 있어서, 상기 피막 형성 조성물이 히드록시프로필 메틸셀룰로오스, 메틸셀룰로오스 및 유드라짓으로 이루어지는 군에서 선택되는 것임을 특징으로 하는 약제 조성물.
- 제 3항에 있어서, 상기 피막 형성 조성물은 장용성 피막 형성 조성물인 것을 특징으로 하는 약제 조성물.
- 제 5항에 있어서, 상기 장용성 피막 형성 조성물은 히드록시프로필 메틸셀룰로오스 프탈레이트 또는 유드라짓 E.S.인 것을 특징으로 하는 약제 조성물.
- 제 1항에 있어서, 과립제, 캅셀제, 정제 또는 피복된 핵정을 함유하는 이중정으로 제조되어짐을 특징으로 하는 약제 조성물.
- 제 7항에 있어서, 상기 피복된 핵정이 라니티딘에 약제학적으로 허용가능한 담체 또는 부형제를 첨가하여 핵정을 제조하고 상기 핵정에 피막 형성 조성물로 피복하여 제조되어짐을 특징으로 하는 약제 조성물.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR1999/000327 WO2000078307A1 (en) | 1999-06-21 | 1999-06-21 | Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020031342A true KR20020031342A (ko) | 2002-05-01 |
KR100453179B1 KR100453179B1 (ko) | 2004-10-15 |
Family
ID=19570891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2001-7016389A KR100453179B1 (ko) | 1999-06-21 | 1999-06-21 | 피복된 라니티딘, 비스마스 서브시트레이트 및수크랄페이트를 함유하는 경구용 위장질환 치료용 약제조성물 |
Country Status (4)
Country | Link |
---|---|
KR (1) | KR100453179B1 (ko) |
CN (1) | CN1173698C (ko) |
AU (1) | AU4655199A (ko) |
WO (1) | WO2000078307A1 (ko) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006103702A2 (en) * | 2005-04-01 | 2006-10-05 | Mccullough Ricky W | Enhanced bio-adherent polymeric compositions for coating mucosal and epidermal epithelium |
CN101507717B (zh) * | 2009-03-13 | 2013-01-23 | 沈阳药科大学 | 一种治疗消化性溃疡的复方片剂及其制备方法 |
CN101607086B (zh) * | 2009-07-21 | 2011-11-02 | 山西安特生物制药股份有限公司 | 一种复方铋剂组合物及其制备方法 |
KR101583452B1 (ko) * | 2015-01-30 | 2016-01-11 | 주식회사 대웅제약 | 위장질환 치료용 의약 조성물 |
KR101801064B1 (ko) | 2015-07-20 | 2017-11-27 | 안국약품 주식회사 | 위장질환 치료용 삼중층 정제 |
KR101794529B1 (ko) * | 2016-06-14 | 2017-11-07 | 주식회사 인트로바이오파마 | 위장질환 치료용 필름코팅정제, 및 이의 제조방법 |
KR20230156474A (ko) | 2022-05-06 | 2023-11-14 | 에니솔루션 주식회사 | 위장질환 치료용 복합정제 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0403048A3 (en) * | 1989-06-14 | 1991-01-30 | Warner-Lambert Company | Medicated compositions containing sucralfate and processes for their production |
JP3677376B2 (ja) * | 1996-08-13 | 2005-07-27 | 武田薬品工業株式会社 | 医薬 |
-
1999
- 1999-06-21 CN CNB998167568A patent/CN1173698C/zh not_active Expired - Lifetime
- 1999-06-21 KR KR10-2001-7016389A patent/KR100453179B1/ko not_active IP Right Cessation
- 1999-06-21 WO PCT/KR1999/000327 patent/WO2000078307A1/en active IP Right Grant
- 1999-06-21 AU AU46551/99A patent/AU4655199A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN1173698C (zh) | 2004-11-03 |
WO2000078307A1 (en) | 2000-12-28 |
KR100453179B1 (ko) | 2004-10-15 |
AU4655199A (en) | 2001-01-09 |
CN1354660A (zh) | 2002-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5631022A (en) | Picosulfate dosage form | |
RU2193880C2 (ru) | Покрытая пленкой таблетка улучшенной безопасности для верхних отделов желудочно-кишечного тракта | |
KR101447909B1 (ko) | 위산 분비의 억제를 위한 조성물 및 방법 | |
US20110008426A1 (en) | Modified release pharmaceutical compositions comprising mycophenolate and processes thereof | |
IL121652A (en) | Pharmaceutical dosage forms for oral administration that include a proton pump inhibitor and a prokinetic substance | |
CA2702356C (en) | Pharmaceutical formulation comprising a proton pump inhibitor for the treatment of gastrointestinal conditions independent of food intake | |
MXPA05001538A (es) | Distribuidor de tipo manguito de endoscopio. | |
EP1043976A1 (en) | Oral pharmaceutical extended release dosage form | |
IE833026L (en) | Controlled absorption pharmaceutical formulation | |
JPH09504280A (ja) | センナ剤形 | |
NZ281236A (en) | Tablet (composition) comprising paracetamol (aceta-minophen) and domperidone (5-chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol -1-yl) propyl]-4-piperidinyl]-1,3-dihydra-2H-benzimidazol-2-one) | |
KR100453179B1 (ko) | 피복된 라니티딘, 비스마스 서브시트레이트 및수크랄페이트를 함유하는 경구용 위장질환 치료용 약제조성물 | |
US20230018600A1 (en) | Controlled release formulations comprising drotaverine or salt thereof | |
CN109890372B (zh) | 含埃索美拉唑的复合胶囊及其制备方法 | |
WO2004062552A2 (en) | Pharmaceutical composition containing a nsaid and a benzimidazole derivative | |
KR20140140353A (ko) | 안정성 및 약물상호작용이 개선된 경구용 복합 정제 조성물 | |
WO2009027786A2 (en) | Matrix dosage forms of varenicline | |
MXPA05004338A (es) | Composiciones de liberacion sostenida que contienen alfuzosin. | |
JP2011521942A (ja) | ユーフォルビア・プロストラータを含有する組成物およびその調製方法 | |
KR102573842B1 (ko) | 방출특성이 우수한 에스오메프라졸 및 탄산수소나트륨의 약제학적 조성물 | |
MXPA05001559A (es) | Composiciones de mononitrato de isosorbide y metodos de uso de las mismas. | |
EP1785135A1 (en) | New stabilized galenic formulations comprising lansoprazole and their preparation | |
KR20140072673A (ko) | 경구용 위장질환 치료를 위한 정제 | |
KR101016832B1 (ko) | 위장관 궤양의 치료를 위한 매스틱 함유 복합제제 | |
KR970006083B1 (ko) | 위장질환 치료용 의약 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
J204 | Request for invalidation trial [patent] | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20080222 Effective date: 20080814 |
|
J301 | Trial decision |
Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20080215 Effective date: 20081112 |
|
J2X1 | Appeal (before the patent court) |
Free format text: INVALIDATION |
|
J302 | Written judgement (patent court) |
Free format text: JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20081204 Effective date: 20090909 |
|
G170 | Publication of correction | ||
FPAY | Annual fee payment |
Payment date: 20130327 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20140306 Year of fee payment: 11 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
FPAY | Annual fee payment |
Payment date: 20150306 Year of fee payment: 12 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20150109 Effective date: 20160125 |
|
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20150714 Effective date: 20160317 Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20150702 Effective date: 20160317 |
|
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20150710 Effective date: 20160324 |
|
FPAY | Annual fee payment |
Payment date: 20160329 Year of fee payment: 13 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2016100001627; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160616 Effective date: 20170105 Free format text: TRIAL NUMBER: 2016100001626; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160616 Effective date: 20170105 Free format text: TRIAL NUMBER: 2016100001625; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160616 Effective date: 20170105 Free format text: TRIAL NUMBER: 2016100001629; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160616 Effective date: 20170105 Free format text: TRIAL NUMBER: 2016100001628; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160616 Effective date: 20170105 Free format text: TRIAL NUMBER: 2016100001630; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160616 Effective date: 20170105 |
|
FPAY | Annual fee payment |
Payment date: 20170403 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20180404 Year of fee payment: 15 |
|
EXPY | Expiration of term |